Optimal sequencing in the treatment of recurrent ovarian cancer

Gynecologic Oncology

Volumn 90, Issue 3 SUPPL., 2003, Pages

  Spriggs, David ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Ovarian cancer; Platinum; Sequencing; Topotecan; Treatment free interval

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM; PROTEIN BCL 2; PROTEIN P53; TAXANE DERIVATIVE; TOPOTECAN;

ANTIGEN DETECTION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CHRONOSEQUENCE; CHRONOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; ECHOGRAPHY; HAND FOOT SYNDROME; HUMAN; LAPAROTOMY; LEUKEMIA; LONG TERM EXPOSURE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT CANCER; SALVAGE THERAPY; SECOND LOOK SURGERY; SHORT COURSE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 0043234491     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00471-2     Document Type: Conference Paper

References (32)

1. Armstrong D.K. Relapsed ovarian cancer challenges and management strategies for a chronic disease . Oncologist. 7:(suppl 5):2002;20-28.
2. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J Clin. 52:2002;23-47.
3. Markman M., Hoskins W. Responses to salvage chemotherapy in ovarian cancer a critical need for precise definitions of the treated population . J Clin Oncol. 10:1992;513-514.
4. Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer implications for patient treatment and the design of phase II trials . Br J Cancer. 59:1989;650-653.
5. Gore M.E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 36:1990;207-211.
6. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadrones L., Lewis J.L. Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
7. Persidis A. Cancer multidrug resistance. Nat Biotechnol. 17:1999;94-95.
8. Petty R., Evans A., Duncan I., Kurbacher C., Cree I. Drug resistance in ovarian cancer - the role of p53. Pathol Oncol Res. 4:1998;97-102.
9. Herzog TJ, Hua J, Horowitz NS, Gibb RK, Mutch DG. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro study. Society of Gynecologic Oncologists 33rd Annual Meeting, 2002;21:A87.
10. Herzog TJ. Clinical experience with topotecan in relapsed ovarian cancer. Gynecol Oncol 2003;90(3):S3-7.
11. Dizon D.S., Hensley M.L., Poynor E.A., Sabbatini P., Aghajanian C., Hummer A., et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma application toward a dynamic disease state model of ovarian cancer . J Clin Oncol. 20:2002;1238-1247.
12. Ledermann J.A. Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR 2.2). Proc Am Soc Clin Oncol. 22:2003;A1794.
13. Kavanagh J., Tresukosol D., Edwards C., Freedman R., Gonzalez de Leon C., Fishman A., Mante R., Hord M., Kudelka A. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol. 13:1995;1584-1588.
14. Spriggs D.R., Leitao M., Hummer A., Dizon D., Carol A., Sabbatini P., Hensley M.L., Venkatraman E. Platinum retreatment of presumed platinum resistant ovarian cancer after nonplatinum therapy. Proc Am Soc Clin Oncol. 21:2002;A877.
15. ten Bokkel Huinink W., Gore M., Carmichael J., Gordan A., Malfetano J., Hudson I., Broom C., Scarabelli C., Davidson N., Spanczynski M., Bolis G., Malmstrom H., Coleman R., Fields S.C., Heron J.F. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 15:1997;2183-2193.
16. Creemers G.J., Bolis G., Gore M., Scarfone G., Lacave A.J., Guastalla J.P., Despax R., Favalli G., Kreinberg R., van Belle S., Hudson I., Verweij J., ten Bokkel Huinink W.W. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer results of a large European phase II study . J Clin Oncol. 14:1996;3056-3061.
17. Hoskins P., Eisenhauer E., Beare S., Roy M., Drouin P., Stuart G., Bryson P., Grimshaw R., Capstick V., Zee B. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer a National Cancer Institute of Canada Clinical Trials Group study . J Clin Oncol. 16:1998;2233-2237.
18. Bookman M.A., Malmström H., Bolis G., Gordon A., Lissoni A., Krebs J.B., Fields S.Z. Topotecan for the treatment of advanced epithelial ovarian cancer an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel . J Clin Oncol. 16:1998;3345-3352.
19. Kudelka A.P., Tresukosol D., Edwards C.L., Freedman R.S., Levenback C., Chantarawiroj P., Gonzalez de Leon C., Kim E.E., Madden T., Wallin B., Hord M., Verschraegen C., Raber M., Kavanagh J.J. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 14:1996;1552-1557.
20. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma a Gynecologic Oncology Group study . J Clin Oncol. 18:2000;1062-1067.
21. Gordon A.N., Granai C.O., Rose P.G., Hainsworth J., Lopez A., Wiessman C., Rosales R., Sharpington T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 18:2000;3093-3100.
22. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma a randomized phase III study of pegylated liposomal doxorubicin versus topotecan . J Clin Oncol. 19:2001;3312-3322.
23. Rose P.G., Blessing J.A., Mayer A.R., Homesley H.D. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma a Gynecologic Oncology Group study . J Clin Oncol. 16:1998;405-410.
24. Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 86:1994;1530-1533.
25. Shapiro J.D., Millward M.J., Rischin D., Michael M., Walcher V., Francis P.A., Toner G.C. Activity of gemcitabine in patients with advanced ovarian cancer responses seen following platinum and paclitaxel . Gynecol Oncol. 63:1996;89-93.
26. Friedlander M., Millward M.J., Bell D., Bugat R., Harnett P., Moreno J.A., Campbell L., Varette C., Ripoche V., Kayitalire L. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 9:1998;1343-1345.
27. von Minckwitz G., Bauknecht T., Visseren-Grul C.M., Neijt J.P. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 10:1999;853-855.
28. Armstrong D., O'Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist. 3:1998;4-10.
29. Armstrong D., Rowinsky E., Donehower R., Rosenshein N., Walczak J., McGuire W. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol. 12:1995;275.
30. Brown J.V., Peters W.A., Rettenmaier M.A., Graham C.L., Smith M.R., Drescher C.W., Micha J.P. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol. 88:2003;136-140.
31. Morris RT. Weekly topotecan in the management of ovarian cancer. Gynecol Oncol 2003;90(3):S34-38.
32. Möbus V, Lane S, Beckman R, Ross G, Kaubitzsch S. Tolerability and survival associated with extended treatment with topotecan in relapsed ovarian cancer - results of a pooled analysis of 523 patients. Int J Gyne Cancer 2000 (suppl.).